BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Endocrine gland cancer AND HLA-A, P01892, 3105, ENSG00000206503, P16188, P30447, P13746, P04439
97 results:

  • 1. Engineered TCR T-cell therapy targeting mass spectrometry-identified natural epitope in PDAC.
    Wang J; Zhang T; Li P; Gai J; Chen S; Espinoza G; Kung HC; Zhang R; Fujiwara K; Fu J; Yu J; Zheng L
    Cancer Lett; 2023 Oct; 573():216366. PubMed ID: 37640197
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Specific human leukocyte antigen class I genotypes predict prognosis in resected pancreatic adenocarcinoma: a retrospective cohort study.
    Wen C; Zhang L; Yang Y; Jin Y; Ren D; Zhang Z; Zou S; Li F; Sun H; Jin J; Lu X; Xie J; Cheng D; Xu Z; Chen H; Mao B; Zhang J; Wang J; Deng X; Peng C; Li H; Jiang C; Lin L; Zhang H; Chen H; Shen B; Zhan Q
    Int J Surg; 2023 Jul; 109(7):1941-1952. PubMed ID: 37026827
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. PRAME and CTCFL-reactive TCRs for the treatment of ovarian cancer.
    van Amerongen RA; Tuit S; Wouters AK; van de Meent M; Siekman SL; Meeuwsen MH; Wachsmann TLA; Remst DFG; Hagedoorn RS; van der Steen DM; de Ru AH; Verdegaal EME; van Veelen PA; Falkenburg JHF; Heemskerk MHM
    Front Immunol; 2023; 14():1121973. PubMed ID: 37026005
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The Detection of Immunity against WT1 and SMAD4
    Koya T; Niida Y; Togi M; Yoshida K; Sakamoto T; Ura H; Togi S; Kato T; Yamada S; Sugiyama H; Koido S; Shimodaira S
    Int J Mol Sci; 2022 Oct; 23(20):. PubMed ID: 36293034
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. KDM5A Inhibits Antitumor Immune Responses Through Downregulation of the Antigen-Presentation Pathway in Ovarian cancer.
    Liu H; Lin J; Zhou W; Moses R; Dai Z; Kossenkov AV; Drapkin R; Bitler BG; Karakashev S; Zhang R
    Cancer Immunol Res; 2022 Aug; 10(8):1028-1038. PubMed ID: 35726891
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. T Cells Engineered to Express Immunoreceptors Targeting the Frequently Expressed Medullary Thyroid cancer Antigens Calcitonin, CEA, and RET M918T.
    Erickson TA; Shih YP; Fass J; Jang M; Tran E
    Thyroid; 2022 Jul; 32(7):789-798. PubMed ID: 35587601
    [No Abstract]    [Full Text] [Related]  

  • 7. The age-dependent association of risk factors with pancreatic cancer.
    Yuan C; Kim J; Wang QL; Lee AA; Babic A; ; Amundadottir LT; Klein AP; Li D; McCullough ML; Petersen GM; Risch HA; Stolzenberg-Solomon RZ; Perez K; Ng K; Giovannucci EL; Stampfer MJ; Kraft P; Wolpin BM
    Ann Oncol; 2022 Jul; 33(7):693-701. PubMed ID: 35398288
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. The interleukin-1 axis and the tumor immune microenvironment in pancreatic ductal adenocarcinoma.
    Herremans KM; Szymkiewicz DD; Riner AN; Bohan RP; Tushoski GW; Davidson AM; Lou X; Leong MC; Dean BD; Gerber M; Underwood PW; Han S; Hughes SJ
    Neoplasia; 2022 Jun; 28():100789. PubMed ID: 35395492
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Identification of Claudin 6-specific HLA class I- and HLA class II-restricted T cell receptors for cellular immunotherapy in ovarian cancer.
    Matsuzaki J; Lele S; Odunsi K; Tsuji T
    Oncoimmunology; 2022; 11(1):2020983. PubMed ID: 35003898
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Cellular and Humoral Immune Responses Induced by an HLA Class I-restricted Peptide cancer Vaccine Targeting WT1 Are Associated With Favorable Clinical Outcomes in Advanced Ovarian cancer.
    Nishida S; Morimoto S; Oji Y; Morita S; Shirakata T; Enomoto T; Tsuboi A; Ueda Y; Yoshino K; Shouq A; Kanegae M; Ohno S; Fujiki F; Nakajima H; Nakae Y; Nakata J; Hosen N; Kumanogoh A; Oka Y; Kimura T; Sugiyama H
    J Immunother; 2022 Jan; 45(1):56-66. PubMed ID: 34874330
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Bioinformatics analysis identified shared differentially expressed genes as potential biomarkers for Hashimoto's thyroiditis-related papillary thyroid cancer.
    Liu C; Pan Y; Li Q; Zhang Y
    Int J Med Sci; 2021; 18(15):3478-3487. PubMed ID: 34522174
    [No Abstract]    [Full Text] [Related]  

  • 12. Anti-cancer immunotherapy using cancer-derived multiple epitope-peptides cocktail vaccination clinical studies in patients with refractory/persistent disease of uterine cervical cancer and ovarian cancer [phase 2].
    Takeuchi S; Kagabu M; Shoji T; Nitta Y; Sugiyama T; Sato J; Nakamura Y
    Oncoimmunology; 2020 Nov; 9(1):1838189. PubMed ID: 33235818
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. hla-a and HLA-DRB1 may play a unique role in ovarian teratoma-associated anti-N-methyl-D-aspartate receptor encephalitis.
    Zhao X; Li J; Zhu Q; Liang G; Xia W; He X; Zhu C; Qi H; Deng B; Chen X; Zhang J
    Reprod Biol Endocrinol; 2020 Nov; 18(1):107. PubMed ID: 33160385
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. Vasculogenic Mesenchymal Tumor: A Clinicopathologic and Molecular Study of 55 Cases of a Distinctive Neoplasm Originating From Mediastinal Yolk Sac Tumor and an Occasional Precursor to Angiosarcoma.
    Levy DR; Agaram NP; Kao CS; Franks SE; Kesler KA; Stram AR; Einhorn LH; Bangs CD; Ulbright TM
    Am J Surg Pathol; 2021 Apr; 45(4):463-476. PubMed ID: 33136584
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Impact of tumor heterogeneity and microenvironment in identifying neoantigens in a patient with ovarian cancer.
    Dao T; Klatt MG; Korontsvit T; Mun SS; Guzman S; Mattar M; Zivanovic O; Kyi CK; Socci ND; O'Cearbhaill RE; Scheinberg DA
    Cancer Immunol Immunother; 2021 May; 70(5):1189-1202. PubMed ID: 33123756
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers.
    Bradley SD; Talukder AH; Lai I; Davis R; Alvarez H; Tiriac H; Zhang M; Chiu Y; Melendez B; Jackson KR; Katailiha A; Sonnemann HM; Li F; Kang Y; Qiao N; Pan BF; Lorenzi PL; Hurd M; Mittendorf EA; Peterson CB; Javle M; Bristow C; Kim M; Tuveson DA; Hawke D; Kopetz S; Wolff RA; Hwu P; Maitra A; Roszik J; Yee C; Lizée G
    Nat Commun; 2020 Oct; 11(1):5332. PubMed ID: 33087697
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Tumor Microenvironment Immune Response in Pancreatic Ductal Adenocarcinoma Patients Treated With Neoadjuvant Therapy.
    Michelakos T; Cai L; Villani V; Sabbatino F; Kontos F; Fernández-Del Castillo C; Yamada T; Neyaz A; Taylor MS; Deshpande V; Kurokawa T; Ting DT; Qadan M; Weekes CD; Allen JN; Clark JW; Hong TS; Ryan DP; Wo JY; Warshaw AL; Lillemoe KD; Ferrone S; Ferrone CR
    J Natl Cancer Inst; 2021 Feb; 113(2):182-191. PubMed ID: 32497200
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. cancer testis antigen Cyclin A1 harbors several hla-a*02:01-restricted T cell epitopes, which are presented and recognized in vivo.
    Teck AT; Urban S; Quass P; Nelde A; Schuster H; Letsch A; Busse A; Walz JS; Keilholz U; Ochsenreither S
    Cancer Immunol Immunother; 2020 Jul; 69(7):1217-1227. PubMed ID: 32157447
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. Identification of germline and somatic mutations in pancreatic adenosquamous carcinoma using whole exome sequencing.
    Ma H; Song B; Guo S; Li G; Jin G
    Cancer Biomark; 2020; 27(3):389-397. PubMed ID: 31958074
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. The clinicopathological and genetic features of ovarian diffuse large B-cell lymphoma.
    Xu H; Duan N; Wang Y; Sun N; Ge S; Li H; Jing X; Liang K; Zhang X; Liu L; Xue C; Zhang C
    Pathology; 2020 Feb; 52(2):206-212. PubMed ID: 31883669
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 5.